Zaid Al-Kadhimi, MD
Associate Professor, Hematology & Medical Oncology
Emory University School of Medicine
Office: The Emory Clinic, Bldg. B
Phone: (404) 778-5984
Fax: (404) 778-3110
For all patient inquiries or appointment requests, please dial (404) 778-1900.
Dr. Zaid Al-Kadhimi joined the Emory faculty in 2014. Prior to his arrival, he worked at Karmanos Cancer Institute at Wayne Staye University in the Bone Marrow Transplant and Immunotherapy program. He is currently a member of the clinical team in the Bone Marrow and Stem Cell Transplant Center at Winship Cancer Institute. He is also a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Dr. Al-Kadhimi's research and training has covered several areas of cancer immunotherapy including adoptive immunotherapy clinical trials, development of Chimeric antigen receptor re-directed T lymphocytes (CARS) targeting various cancers. Additionally, he has worked in the laboratory to analyze G-CSF mobilized grafts for various immune suppressive cellular components, which helped in developing applications to deplete these immune suppressive cells and improve immune reconstitution post-transplant. In the past decade, he has opened several investigator initiated therapeutic trials in autologous, allogeneic related, unrelated, and haplo identical hematopoietic stem cell transplants.
His primary area of interest is transplant immunology and applications to use both autologous and allogeneic transplants as platforms for cellular therapy and cancer immunotherapy. One exciting accomplishment is the low rate of aGVHD and good survival in MUDs with Tacrolimus/Sirolimus and Thymoglobulin Phase II trial. Encouraging long term outcomes were observed with very low long term complication incidence and quality of life.
- Depletion of immune suppressor cells from autologous graft with the goal of improving immune reconstitution and anti-tumor immune response post-transplant. In a small investigator initiated trial with immune correlative studies (day 15 lymphocyte/ monocyte recovery and phenotype), which can be compared with base line. Preliminary data can be used for a R21 proposal. Such trial has a potential of changing the paradigm of autologous transplant.
- Prevention of GVHD both acute and chronic post unrelated transplants (From HLA 8/8 and 7/8 matched donors). Based on encouraging results we observed in reducing GVHD rates with triple immune suppression strategy, I hope to further develop this regimen to reduce non relapse mortality (NRM) at 1 and 5 years post-transplant. Reducing NRM without increasing relapse can improve overall transplant outcomes. Furthermore, this strategy can be well complemented with low dose DLI post-transplant to further prevent relapse.
- Develop haploidentical transplant. I will focus on having a transplant platform of: enriched donor innate immune cells, enriched host homeostatic cytokines, and depleted donor adaptive immune cells early post-transplant. Such a platform will allow for in vivodonor innate cell activating interventions with the goal of generating allo reactive innate immune response (GVL) without GVHD.
View clinical trials at Winship Cancer Institute